# DESCRIPTION

- introduce inhibitors of nicotinamide adenyl dinucleotide
- motivate use in inflammatory diseases
- describe embodiments of the invention
- define terms
- describe nicotinamide adenyl dinucleotide biosynthesis
- introduce inhibitor of nicotinamide adenyl dinucleotide formation
- describe benefits of the present invention
- describe use of inhibitor for treatment of inflammatory diseases
- describe preferred embodiment of the inhibitor
- describe structure of the inhibitor
- define compound of formula (I)
- specify substituents of formula (I)
- provide further preferred embodiments of formula (I)
- describe especially preferred embodiment of formula (I)
- list exemplary compounds
- describe use of inhibitors for treating diseases
- define medicament manufacturing process
- describe pharmaceutical compositions
- outline treatment methods

## EXAMPLES

### Example 1

- illustrate relationship between NAD levels and pro-inflammatory cytokine secretion

### Example 2

- describe inhibition of pro-inflammatory cytokines production by FK866

### Example 3

- illustrate inhibition of TNFÎ± secretion at posttranscriptional level

### Example 4

- describe inhibition of other pro-inflammatory cytokine production by FK866

### Example 5

- illustrate correlation between pro-inflammatory cytokine secretion and NAD levels

### Example 6

- show inhibition of pro-inflammatory cytokine secretion is not due to apoptosis induction

### Example 7

- illustrate NAMPT is the only molecular target of FK866

### Example 8

- describe reduction of disease severity of rheumatoid arthritis in an experimental mouse model

### Example 9

- describe upregulation of NAMPT expression in collagen-induced arthritis
- illustrate NAMPT expression in arthritic joints

